These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 12673114)

  • 1. Histone deacetylase inhibitors in cancer therapy.
    Rosato RR; Grant S
    Cancer Biol Ther; 2003; 2(1):30-7. PubMed ID: 12673114
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HDAC Inhibitors.
    Olzscha H; Bekheet ME; Sheikh S; La Thangue NB
    Methods Mol Biol; 2016; 1436():281-303. PubMed ID: 27246222
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nuclear factor-kappaB p65 small interfering RNA or proteasome inhibitor bortezomib sensitizes head and neck squamous cell carcinomas to classic histone deacetylase inhibitors and novel histone deacetylase inhibitor PXD101.
    Duan J; Friedman J; Nottingham L; Chen Z; Ara G; Van Waes C
    Mol Cancer Ther; 2007 Jan; 6(1):37-50. PubMed ID: 17237265
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Histone deacetylase inhibitors promote osteoblast maturation.
    Schroeder TM; Westendorf JJ
    J Bone Miner Res; 2005 Dec; 20(12):2254-63. PubMed ID: 16294278
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Histone deacetylase inhibitors induce attenuation of Wnt signaling and TCF7L2 depletion in colorectal carcinoma cells.
    Götze S; Coersmeyer M; Müller O; Sievers S
    Int J Oncol; 2014 Oct; 45(4):1715-23. PubMed ID: 25050608
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Histone deacetylase inhibitors induce cell death and enhance the susceptibility to ionizing radiation, etoposide, and TRAIL in medulloblastoma cells.
    Sonnemann J; Kumar KS; Heesch S; Müller C; Hartwig C; Maass M; Bader P; Beck JF
    Int J Oncol; 2006 Mar; 28(3):755-66. PubMed ID: 16465382
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Histone deacetylase inhibitors promote STI571-mediated apoptosis in STI571-sensitive and -resistant Bcr/Abl+ human myeloid leukemia cells.
    Yu C; Rahmani M; Almenara J; Subler M; Krystal G; Conrad D; Varticovski L; Dent P; Grant S
    Cancer Res; 2003 May; 63(9):2118-26. PubMed ID: 12727828
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Histone deacetylase inhibitors: a novel target of anticancer therapy (review).
    Kouraklis G; Theocharis S
    Oncol Rep; 2006 Feb; 15(2):489-94. PubMed ID: 16391874
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Class 1-Selective Histone Deacetylase (HDAC) Inhibitors Enhance HIV Latency Reversal while Preserving the Activity of HDAC Isoforms Necessary for Maximal HIV Gene Expression.
    Zaikos TD; Painter MM; Sebastian Kettinger NT; Terry VH; Collins KL
    J Virol; 2018 Mar; 92(6):. PubMed ID: 29298886
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Histone deacetylase inhibitors: molecular and biological activity as a premise to clinical application.
    Santini V; Gozzini A; Ferrari G
    Curr Drug Metab; 2007 May; 8(4):383-93. PubMed ID: 17504226
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Histone deacetylase inhibitor enhances the anti-leukemic activity of an established nucleoside analogue.
    Acharya MR; Figg WD
    Cancer Biol Ther; 2004 Aug; 3(8):719-20. PubMed ID: 15254393
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Histone deacetylase inhibitors and aspirin interact synergistically to induce cell death in ovarian cancer cells.
    Sonnemann J; Hüls I; Sigler M; Palani CD; Hong le TT; Völker U; Kroemer HK; Beck JF
    Oncol Rep; 2008 Jul; 20(1):219-24. PubMed ID: 18575740
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Histone deacetylase inhibitors - molecular mechanisms of actions and clinical applications].
    Grabarska A; Dmoszyńska-Graniczka M; Nowosadzka E; Stepulak A
    Postepy Hig Med Dosw (Online); 2013 Aug; 67():722-35. PubMed ID: 24018438
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Histone deacetylase inhibitors induce cell death and enhance the apoptosis-inducing activity of TRAIL in Ewing's sarcoma cells.
    Sonnemann J; Dreyer L; Hartwig M; Palani CD; Hong le TT; Klier U; Bröker B; Völker U; Beck JF
    J Cancer Res Clin Oncol; 2007 Nov; 133(11):847-58. PubMed ID: 17486365
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Histone deacetylase inhibitors promote the tumoricidal effect of HAMLET.
    Brest P; Gustafsson M; Mossberg AK; Gustafsson L; Duringer C; Hamiche A; Svanborg C
    Cancer Res; 2007 Dec; 67(23):11327-34. PubMed ID: 18056459
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of histone deacetylase inhibitors in the treatment of cancer (Review).
    Mei S; Ho AD; Mahlknecht U
    Int J Oncol; 2004 Dec; 25(6):1509-19. PubMed ID: 15547685
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeted histone deacetylase inhibition for cancer therapy.
    Vigushin DM; Coombes RC
    Curr Cancer Drug Targets; 2004 Mar; 4(2):205-18. PubMed ID: 15032670
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Histone deacetylase inhibitors and anticancer therapy.
    Kouraklis G; Theocharis S
    Curr Med Chem Anticancer Agents; 2002 Jul; 2(4):477-84. PubMed ID: 12678732
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A review of depsipeptide and other histone deacetylase inhibitors in clinical trials.
    Piekarz R; Bates S
    Curr Pharm Des; 2004; 10(19):2289-98. PubMed ID: 15279609
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibitors of histone deacetylase as new anticancer agents.
    Jung M
    Curr Med Chem; 2001 Oct; 8(12):1505-11. PubMed ID: 11562279
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.